Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 34508654

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2021 Sep 25
First author
Hutchings M

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 Sep 25;398(10306):1109-1110. doi: 10.1016/S0140-6736(21)01070-9.
    note
    Source null
    related pmid
    34508653
    relationship
    Comment in

Authors and identifiers

  1. name
    Hutchings M
    type
    Author
  2. name
    Mous R
    type
    Author
  3. name
    Clausen MR
    type
    Author
  4. name
    Johnson P
    type
    Author
  5. name
    Linton KM
    type
    Author
  6. name
    Chamuleau MED
    type
    Author
  7. name
    Lewis DJ
    type
    Author
  8. name
    Sureda Balari A
    type
    Author
  9. name
    Cunningham D
    type
    Author
  10. name
    Oliveri RS
    type
    Author
  11. name
    Elliott B
    type
    Author
  12. name
    DeMarco D
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Hutchings M
    type
    Author
  2. name
    Mous R
    type
    Author
  3. name
    Clausen MR
    type
    Author
  4. name
    Johnson P
    type
    Author
  5. name
    Linton KM
    type
    Author
  6. name
    Chamuleau MED
    type
    Author
  7. name
    Lewis DJ
    type
    Author
  8. name
    Sureda Balari A
    type
    Author
  9. name
    Cunningham D
    type
    Author
  10. name
    Oliveri RS
    type
    Author
  11. name
    Elliott B
    type
    Author
  12. name
    DeMarco D
    type
    Author
bibliography ids
  1. nci-bib-1968864472269bd05434339f
book metadata
content sha256
9bb297641da2b61df5758d8e3a23a4000184d41d1ff0fa5e777f0926975b2f67
document type
citation
dois
  1. 10.1016/S0140-6736(21)00889-8
electronic publication date
display
2021 Sep 8
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34508654
immutable id
pubmed:34508654@9bb297641da2b61df5758d8e3a23a4000184d41d1ff0fa5e777f0926975b2f67
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10306
name
Lancet (London, England)
nlm unique id
2985213R
pages
1157-1169
volume
398
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 Sep 25;398(10306):1109-1110. doi: 10.1016/S0140-6736(21)01070-9.
    note
    Source null
    related pmid
    34508653
    relationship
    Comment in
outcomes validated
false
pmid
34508654
provenance
batch id
192b6392c165c6b06274
provider
NCBI PubMed ESummary
record sha256
5ac13e1cf89c4f7b82ee3c2464787186011a06dcbe87c2e41e65df12f012a33e
response sha256
7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
retrieved at
2026-09-09T23:48:02.713075+00:00
publication date
display
2021 Sep 25
precision
day
year
2021
publication types
  1. Clinical Trial, Phase I
  2. Clinical Trial, Phase II
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34508654/
title
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.

Preserved source evidence · Independent clinical review pending · Not medical advice